Is there a need for a new generation of vaccines against pertussis? (Q36458388)

14 August 2017

title

Is there a need for a new generation of vaccines against pertussis? (English)

1 reference

14 August 2017

Jann Storsaeter

1

1 reference

14 August 2017

Joanne Wolter

series ordinal

2

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

Expert Opinion on Emerging Drugs

14 August 2017

published in

1 reference

14 August 2017

volume

11

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

195-205

1 reference

Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Canadian experience with implementation of an acellular pertussis vaccine booster-dose program in adolescents: implications for the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Pertussis of adults and infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Duration of immunity against pertussis after natural infection or vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Whooping cough--a continuing problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

An epizootic of whooping cough among chimpanzees in a zoo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Systematic review of the effects of pertussis vaccines in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Development of acellular pertussis vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Pertussis in Sweden after the cessation of general immunization in 1979.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

21 January 2018

Pertussis in the Adult

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Are vaccination programs and isolate polymorphism linked to pertussis re-emergence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Antibodies to BrkA augment killing of Bordetella pertussis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Crucial role of antibodies to pertactin in Bordetella pertussis immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Efficacy of a two-component acellular pertussis vaccine in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Immunity to Bordetella pertussis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Extensive limb swelling after immunization: reports to the Vaccine Adverse Event Reporting System

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Bordetella pertussis from functional genomics to intranasal vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Applying peptide antigens onto bare skin: induction of humoral and cellular immune responses and potential for vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Neonatal and early life vaccinology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Characterization of bactericidal immune responses following vaccination with acellular pertussis vaccines in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Clinical characteristics of illness caused by Bordetella parapertussis compared with illness caused by Bordetella pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Multiple roles for Bordetella lipopolysaccharide molecules during respiratory tract infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Bordetella pertussis virulence factors affect phagocytosis by human neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Adenylate cyclase toxin from Bordetella pertussis synergizes with lipopolysaccharide to promote innate interleukin-10 production and enhances the induction of Th2 and regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Neutralizing antibodies to adenylate cyclase toxin promote phagocytosis of Bordetella pertussis by human neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Determination of serum antibody to Bordetella pertussis adenylate cyclase toxin in vaccinated and unvaccinated children and in children and adults with pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin tests with vaccine antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Eighty-kilodalton N-terminal moiety of Bordetella pertussis filamentous hemagglutinin: adherence, immunogenicity, and protective role

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Aluminium adjuvants--in retrospect and prospect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Effects of lowering the aluminium content of a dTpa vaccine on its immunogenicity and reactogenicity when given as a booster to adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Overview of vaccine adjuvants: present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Vaccine adjuvants: current state and future trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

DNA vaccines: progress and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

DNA vaccine encoding pertussis toxin S1 subunit induces protection against Bordetella pertussis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

21 January 2018

Non-parenteral vaccines

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Immunogenicity of a three-component acellular pertussis vaccine administered at birth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Can successful vaccines teach us how to induce efficient protective immune responses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Pertussis in a previously immunized child with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Efficacy of an acellular pertussis vaccine among adolescents and adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

New Pertussis Vaccination Strategies beyond Infancy: Recommendations by the Global Pertussis Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Outbreak of pertussis in highly immunized adolescents and its secondary spread to their families.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Hospitalization and complications in children under 2 years of age with Bordetella pertussis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

A search for serologic correlates of immunity to Bordetella pertussis cough illnesses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Serological correlates in whooping cough

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Cell‐Mediated Immunity and Antibody Responses toBordetella pertussisAntigens in Children with a History of Pertussis Infection and in Recipients of an Acellular Pertussis Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. The Progetto Pertosse-CMI Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Alternative routes of immunization for prevention of infectious diseases: a new paradigm for the 21st century.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Bordetella adenylate cyclase is a virulence associated factor and an immunoprotective antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Protective activity of Bordetella adenylate cyclase-hemolysin against bacterial colonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

The protein content of diphtheria-tetanus toxoids-acellular pertussis vaccines and an emerging clinical problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Bordetella pertussis surveillance in England and Wales: 1995-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Effects of adsorption of acellular pertussis antigens onto different aluminium salts on the protective activity in an intranasal murine model of Bordetella pertussis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

What are the limits of adjuvanticity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Bordetella pertussis can act as adjuvant as well as inhibitor of immune responses to non-replicating nasal vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Immunization and antibody response in the newborn infant. I. Pertussis inoculation within twenty-four hours of birth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Vaccine development strategies for improving immunization: the role of modern immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

Experimental Whooping Cough

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.195

10.1517/14728214.11.2.195

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference